Omidubicel Non-Cultured Fraction

CHEMBL6068497 Phase 4 Aprovado Cell

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

The non-cultured cellular fraction of omidubicel, comprising unmodified cord blood cells that are co-infused alongside the expanded stem cells to provide early immune reconstitution. This component supports the body's initial immune recovery while the expanded cells establish long-term engraftment.

Áreas Terapêuticas

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

The non-cultured cellular fraction of omidubicel, comprising unmodified cord blood cells that are co-infused alongside the expanded stem cells to provide early immune reconstitution. This component supports the body's initial immune recovery while the expanded cells establish long-term engraftment.

Yes, Omidubicel Non-Cultured Fraction is an approved drug. It has reached clinical phase 4. It is classified as a Cell.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068497. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Omidubicel Non-Cultured Fraction no PillFYI

Dados Rápidos

Sinônimos: 1

Links Externos

ChEMBL CHEMBL6068497

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.